Drugs / Ferroquine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00563914 | Oct 2007 → Nov 2008 | malaria | Sanofi | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT03660839 | Sep 2018 → Nov 2019 | Plasmodium falciparum malaria | Sanofi | Completed | Missed primary |
| Phase 2 | NCT02497612 | Jul 2015 → Sep 2019 | Plasmodium falciparum malaria | Sanofi | Terminated | Missed primary |
| Phase 2 | NCT00988507 | Oct 2009 → Nov 2010 | Plasmodium falciparum malaria | Sanofi | Terminated | Met primary Stop: Business |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05911828 Comparator | Aug 2024 → Feb 2025 | Plasmodium falciparum malaria | Zydus Lifesciences Limited | Unknown | No outcome recorded |
| Phase 2 | NCT04264130 Comparator | Jul 2018 → Dec 2019 | urinary schistosomiasis | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ferroquine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911828 ↗ |
| Known as | SSR97193 | “Ferroquine (SSR97193)” NCT03660839 ↗ |
| Modality | Small molecule | “Ferroquine, a 4-aminoquinolone, is a novel long-acting combination partner” PMID 28722611 ↗ Jul 2017 |
| Route | Oral | “Route of administration: oral” NCT00988507 ↗ |